Trump said he doesn't see a recession after the bond market spooked investors and the Dow suffered its worst day of the year last week.Marketsread more
Ahead of the deadline, U.S. President Donald Trump told reporters that Huawei was a national security threat.Technologyread more
Baidu is gearing up to release its second-quarter earnings on Monday with the market expecting a sharp decline in profit.Technologyread more
Americans now say they approve of free trade by 64%-27%, a margin of better than two to one. That's up from 57%-37% early in Trump's presidency, and 51%-41% near the end of...Politicsread more
Stocks in Asia rose on Monday as U.S. Treasury yields bounced higher after plunging last week.Asia Marketsread more
The problem with tanking equities lies elsewhere, writes Michael Ivanovitch, because traders see no end to America's unfolding trade disputes with Europe and China.World Economyread more
Beijing wants to use reforms to support a slowing economy.China Marketsread more
Trump said Cook made a "good case" that it would be difficult for Apple to pay tariffs, when Samsung does not face the same hurdle because much of its manufacturing is in...Technologyread more
The yield on the benchmark 10-year Treasury note briefly fell below the 2-year rate on Wednesday, a phenomenon in the bond market known as yield curve inversion, which is...Marketsread more
Despite aggressive strides, Waymo needs one thing before their self-driving cars become a seriously useful transportation system: people. We talked to the ones closest to it.Technologyread more
The hearing will now begin next Monday to allow time for the completion of a previous trial that revolves around former 1MDB unit SRC International, a Kuala Lumpur High Court...Asia Newsread more
(Adds details on Eylea, Dupixent sales, background)
Aug 6 (Reuters) - Regeneron Pharmaceuticals Inc beat analysts' estimates for second-quarter profit and revenue on Tuesday, boosted by demand for its blockbuster eye treatment Eylea and eczema drug Dupixent.
Sales of Eylea, which treats diseases of the eye including age-related macular degeneration, jumped 17% in the United States in the latest quarter even as it faces competition from Roche Holding AG and Novartis AG's Lucentis.
Eylea's sales of $1.16 billion also topped expectations of about $1.10 billion, according to consensus estimates compiled by brokerage Credit Suisse.
The drug, which accounts for more than half of total revenue, is expected to lose its patents in the next five years
To reduce its reliance on Eylea, Regeneron is focusing on Dupixent and has massed up approvals for three major diseases including asthma and nasal polyps since the drug was approved in 2017.
Dupixent's quarterly sales jumped nearly three-fold to $557.3 million.
Total revenue rose 20.3% to $1.93 billion in the second quarter ended June 30, beating the average analyst estimate of $1.80 billion, according to IBES data from Refinitiv.
Excluding one-time items, the company earned $6.02 per share, above the average analyst estimate of $5.41.
(Reporting by Manas Mishra and Shivani Singh; Editing by Maju Samuel and Sriraj Kalluvila)